In Vitro Evaluation of High Mobility Group Box 1 Protein Removal with Various Membranes for Continuous Hemofiltration

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 4, 2011, Pages 385-393

  Yumoto, Miho ^a   Nishida, Osamu ^a   Moriyama, Kazuhiro ^a   Shimomura, Yasuyo ^a   Nakamura, Tomoyuki ^a   Kuriyama, Naohide ^a   Hara, Yoshitaka ^a   Yamada, Shingo ^b  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINO TEST CORPORATION   (Japan)

Author keywords

Experimental model; Hemofiltration; HMGB1 protein; Polyacrylonitrile; Sepsis

Indexed keywords

BOVINE SERUM ALBUMIN; HIGH MOBILITY GROUP B1 PROTEIN; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE;

ARTICLE; CIRCULATION; FILTER; HEMOFILTRATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN METABOLISM; SEPSIS; SUBSTITUTION THERAPY;

ADSORPTION; CYTOKINES; HEMOFILTRATION; HMGB1 PROTEIN; HUMANS; MEMBRANES, ARTIFICIAL; POROSITY; SEPSIS; SERUM ALBUMIN, BOVINE;

EID: 80052001687     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00971.x     Document Type: Article

References (23)

1. Wang H, Bloom O, Zhang M etal. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
2. Park JS, Gamboni-Robertson F, He Q etal. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24.
3. Tracey KJ, Fong Y, Hesse DG etal. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-4.
4. Ulloa L, Ochani M, Yang H etal. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002;99:12351-6.
5. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
6. Ronco C, Tetta C, Mariano F etal. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
7. Honoré PM, Jamez J, Wauthier M etal. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-7.
8. Ronco C, Kellum JA, Bellomo R etal. Potential interventions in sepsis-related acute kidney injury. Clin J Am Soc Nephrol 2008;3:531-44.
9. Hirasawa H, Oda S, Matsuda K. Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. Contrib Nephrol 2007;156:365-70.
10. De Vriese AS, Colardyn FA, Philippé JJ etal. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-53.
11. Morgera S, Haase M, Kuss T etal. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099-104.
12. Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J, Rauvala H. 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. J Biol Chem 1991;266:16722-9.
13. Chanard J, Lavaud S, Paris B etal. Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. preclinical studies. ASAIO J 2005;51:342-7.
14. Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I. New high mobility group box 1 assay system. Clin Chim Acta 2006;372:173-8.
15. Moriyama K, Soejima Y. Continuous hemodiafiltration using PMMA membrane: clinical efficacy and its mechanisms. Contrib Nephrol 1999;125:222-32.
16. Yamada S, Maruyama I. HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007;375:36-42.
17. Yang H, Ochani M, Li J etal. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101:296-301.
18. Suda K, Takeuchi H, Hagiwara T etal. Spherical sulfated cellulose adsorbs high-mobility-group box chromosomal protein 1 In Vitro and In Vivo. ASAIO J 2010;56:210-4.
19. Yamamoto T, Ono T, Ito T, Yamanoi A, Maruyama I, Tanaka T. Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats. Crit Care Med 2010;38:879-85.
20. Wang H, Ward MF, Sama AE. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009;32:348-57.
21. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989;9:21-32.
22. Dahaba AA, Elawady GA, Rehak PH, List WF. Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care 2002;30:269-74.
23. Nishida O, Nakamura T, Kuriyama N etal. Sustained high-efficiency daily diafiltration using a cytokine-adsorbing membrane in the treatment of patients with severe sepsis. Crit Care 2011;15(Suppl 1) (abstract):P115.